Why the study?
Adipose tissue expansion is a major risk factor for cardiometabolic disease, and epicardial adipose tissue-secreted microRNAs may modulate cardiac disease progression as early biomarkers and therapeutic targets.
Key points are not available for this paper at this time.
Design
Review
Epicardial adipose tissue-secreted microRNAs play a key role in modulating cardiac disease progression and may serve as early biomarkers and therapeutic targets for cardiometabolic disease.
Adipose tissue expansion and subsequent metabolic dysfunction has been considered one of the major risk factors for development of cardiometabolic disease. Epicardial adipose tissue (EAT) in particular is a unique subtype of visceral adipose tissue located on the surface of the heart, around the coronary arteries. Due to its proximity, EAT can modulate the local metabolic and immune function of cardiomyocytes and coronary arteries. Several microRNAs have been described as key players in both cardiac and vascular function that when dysregulated will contribute to dysfunction. Here we review the influence of obesity in the crosstalk between specific adipose tissue types, in particular the EAT-secreted microRNAs, as key modulators of cardiac disease progression, not only as early biomarkers but also as therapeutic targets for cardiometabolic disease.
No takes yet. Share an insight, caveat, or question.
Santos et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: